Conference Reports for NATAP

Back

The Liver Meeting Washington DC October 2017     Summary from AASLD 2017 for Hepatitis C HCV: Game over? - Jurgen K. Rockstroh M.D., Professor of Medicine Department of Medicine I, University Hospital Bonn, Bonn, Germany - (11/29/17)   Burden of Illness Economic Model for Patients with Non-alcoholic Steatohepatitis (NASH) in the United States - (12/19/17)   The Global Epidemiology of Non-alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Systematic Review and Meta-analysis - (12/19/17)   Long-Term Outcomes of Diabetic Patients with Non-alcoholic Fatty Liver Disease (NAFLD) / HIV & the Liver, Fatty Liver/NALFD - (12/18/17)   Hepatocellular Carcinoma (HCC) in Patients with Non-Cirrhotic and Cirrhotic Nonalcoholic Fatty Liver Disease - (12/15/17)   Mean Week 24 HBsAg Declines Predict Subsequent Rate of HBsAg Seroclearance and Could Be a Valuable Endpoint for Early Development HBV Trials - (12/05/17)   The HBV capsid assembly modulator JNJ-379 is a potent inhibitor of viral replication across full length genotype A-H clinical isolates in vitro - (12/05/17)   AL-034 (or TQ-A3334), a Selective Toll-like Receptor 7 Agonist for Oral Treatment of Chronic Hepatitis B Virus Infection - (12/05/17)   AASLD 2017 Viral Hepatitis Debrief - (12/05/17)   Survival Benefit of Direct-Acting Antiviral Therapy in Patients with Decompensated Cirrhosis - (12/05/17)   Failure to multiple Interferon-free direct Antiviral therapies: could Chronic hepatitis C become incurable? - (12/02/17)   HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in HBeAg-Positive and Negative Virally SuppressedPatientsWith Hepatitis B - (12/02/17)   HBcrAg, HBV-RNA Declines in A Phase 2a Study Evaluating the Multi-Dose Activity of ARB-1467 in HBeAg-Positive and Negative Virally SuppressedPatientsWith Hepatitis B - (12/02/17)   Prospective, Randomized Assessment of HBV-associated and Other Clinical Outcome Events During Long-Term Therapy With Entecavir or Other HBV Nucleos(t)ide Analogues in Patients With Chronic HBV Infection - (12/02/17)   Prospective, Randomized Assessment of HBV-associated and Other Clinical Outcome Events During Long-Term Therapy With Entecavir or Other HBV Nucleos(t)ide Analogues in Patients With Chronic HBV Infection - (12/02/17)   Virology analyses from HCV-infected patients treated with the combination of AL-335 and odalasvir, with and without simeprevir, in Phase II studies - (12/02/17)   Hepatitis C Care in the Department of Veterans Affairs: HIT Process Improvement Program - (11/29/17)   Cardiovascular risk in NAFLD- not an equal opportunity: implications for women's health - (11/29/17)   No Evidence of 1-Year Reinfection after Treating HCV at a Methadone Program - (11/29/17)   C-BREEZE 1: Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection - (11/29/17)   Survival Benefit of Direct-Acting Antiviral Therapy in Patients with Decompensated Cirrhosis - (11/29/17)   Novel multiparametric magnetic resonance elastography (MRE) protocol accurately predicts early NASH and disease activity - (11/29/17)   NAFLD Debrief AASLD 2017 - (11/29/17)   Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/29/17)   Multi-Biomarker Validation of MRI-PDFF- and MRE-Derived Treatment Response with BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)   Baseline Serum Pro-C3 Predicts Response to BMS-986036 (PEG-FGF21): A Secondary Analysis of a Multi-Center Clinical Trial in Non-Alcoholic Steatohepatitis (NASH) - (11/29/17)   Failure to multiple Interferon-free direct Antiviral therapies: could Chronic hepatitis C become incurable? - (11/27/17)   Can HCV be eliminated among HIV---infected MSM in Berlin? Modeling a setting with increasing incidence and high treatment rates - (11/27/17)   Effectiveness of Elbasvir/Grazoprevir in Patients With Chronic Hepatitis C and Chronic Kidney Disease:Results From the Veterans Affairs System - (11/27/17)   Sofosbuvir/Velpatasvir for 12 Weeks in Genotype 1-4 HCV-Infected Liver Transplant Recipients - (11/27/17)   Efficacy and Safety of Glecaprevir / Pibrentasvir in Patients Infected with HCV GT1 - 3 by Renal Impairment Status: A Pooled Analysis of Two Phase 3 Japanese Trials - (11/27/17)   Real World Effectiveness of 8 and 12 Weeks of Ledipasvir/Sofosbuvir (LDV/SOF) in Blacks with HCV: A Comparative Analysis of Clinical Trials with Real World Cohorts - (11/27/17)   Long-term Follow-Up of Patients With Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR With DAA-Based Therapy: Results From the Gilead SVR Registry - (11/27/17)   Real-World Study Shows ZEPATIER® (Elbasvir and Grazoprevir) Resulted in High Rates of Sustained Virologic Response in Patients with Chronic Hepatitis C Infection Who Have Chronic Kidney Disease - (11/27/17)   Serious adverse events and direct-acting antivirals drugs (DAA): ANRS CO22 HEPATHER cohort - (11/27/17)   Safety and Efficacy of Glecaprevir / Pibrentasvir in Patients with Chronic Hepatitis C Genotypes 1 - 6 and Recent Drug Use - (11/27/17)   Development and Validation of the Collagen Neo-Epitope Biomarker Pro-C3 "FIB-C3 Score" for Detection and Staging of Advanced Non-Alcoholic Fatty Liver Disease in a Large International Multi-Centre Patient Cohort - (11/20/17)   Prevalence and Clinical Characteristics of Nonalcoholic Fatty Liver Disease in Lean Subjects in Comparison with Overweight or Obese Individuals: A cross-sectional study - (11/20/17)   Advanced machine learning techniques to identify a panel of biomarkers that identify non-alcoholic steatohepatitis - (11/20/17)   Diagnosing NASH and Assessing NASH Disease Severity with HepQuant-STAT, a Simple Quantitative Liver Function Test - (11/20/17)   Serum-Based Biomarker Test Accurately Stratifies Hepatic Fibrosis in Patients with Nonalcoholic Steatohepatitis - (11/20/17)   CM-101 a novel CCL24 blocking monoclonal antibody ameliorates hepatic injury in NASH induced mouse model - (11/20/17)   Significant anti-fibrotic efficacy of EDP-305, a highly potent and selective farnesoid X receptor (FXR) agonist, in a rat model of thioacetamide-induced liver fibrosis and cirrhosis - (11/20/17)   Cure denied and cure delayed in Chronic Hepatitis C; monitoring non-start rates and increased time to start using real-world data from the TRIO Network - (11/20/17)   Access to HCV Care for 31,154 Patients in the United States Real-world experience from the TRIO Network - (11/20/17)   Impact of Hepatocellular Carcinoma (HCC) and Tumor Treatment on Sustained Virologic Response (SVR) Rates with Direct-Acting Antiviral (DAA) Therapy for Hepatitis C: HCV-TARGET Results - (11/20/17)   Treatment of HCV-induced cryoglobulinemic vasculitis with new direct acting antiviral (DAA) regimens - (11/20/17)   Safety and Efficacy of Velpatasvir and Sofosbuvir-based Regimens for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study - (11/20/17)   The Long-Term Clinical Course of Histologically Advanced NAFLD. Impact of Fibrosis Severity on Major Clinical Outcomes. - An International and Multicenter Cohort Study - (11/17/17)   Natural History of Nonalcoholic Fatty Liver Disease in Children - (11/17/17)   Evaluation of an early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C patients treated with All-Oral DAAs - (11/17/17)   Real life clinical outcomes in DAA-treated and untreated patients with HCV advanced liver disease. Interim one year data from the ongoing PITER cohort - (11/17/17)   Long-term Follow-Up of Patients With Chronic HCV and No or Minimal Fibrosis Shows Low Risk for Liver-Related Morbidity and Mortality After Achieving SVR With DAA-Based Therapy: Results From the Gilead SVR Registry - (11/16/17)   Low Rates of De Novo or Recurrent Hepatocellular Carcinoma in HCV Cirrhotic Patients Treated with Direct-Acting Antivirals (DAAs): A Single-Center Experience - (11/16/17)   HCC Trends, Disparities in Tumor Stage at Diagnosis - Less Than Half of Hepatocellular Carcinoma Patients Among the 1945-1965 Birth Cohort in the U.S. Were Within Milan Criteria at Time of Diagnosis - (11/16/17)   Routine Hepatocellular Carcinoma Surveillance for Hepatitis C Virus-Infected Alaska Native Persons Associated with Increased Likelihood of HCC Diagnosis at an Early Stage During 1991-2016 - (11/16/17)   Economic Burden of Chronic Hepatitis C (CHC) in Medicaid and Commercially Insured Patients in the United States - (11/16/17)   Utilization and Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment Naïve (TN) Genotype 1a (GT1A) Chronic Hepatitis C Virus (HCV) Patients with/without Baseline NS5A resistance-associated substitutions (RASs) - (11/16/17)   Epidemiologic Impact of Expanding Chronic Hepatitis C (CHC) Treatment in People Who Inject Drug in the United States: A Mathematical Model Using Data From the C-EDGE CO-STAR Study - (11/16/17)   Evaluation of Cytochrome P450- and Transporter-Mediated Drug-Drug Interactions Between the Apoptosis Signal-Regulating Kinase 1 (ASK1) Inhibitor Selonsertib and Phenotypic Probe Substrates or Prototypic Inhibitors/Inducers - (11/16/17)   Radiologic Progression in Primary Sclerosing Cholangitis by Two-Dimensional Magnetic Resonance Cholangiopancreatography: Prospective Data From a Randomized Controlled Trial - (11/16/17)   Quantification of Biliary Tree Volume in Patients With PSC Using Three-Dimensional Reconstruction of Magnetic Resonance Cholangiopancreatography: Clinical Associations and Prognostic Significance - (11/16/17)   Identification of Circulating MicroRNAs Altered by an Apoptosis Signal-Regulating Kinase 1 Inhibitor in a Fast-food Diet NAFLD Mouse Model - (11/14/17)   Plasma Metabolites for de Novo Lipogenesis and Pharmacodynamic Activity of Acetyl-CoA Carboxylase Inhibitor GS-0976 - (11/14/17)   Variability in Measurement of Hepatic Venous Pressure Gradient in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis: Results From a Randomized, Controlled Trial - (11/14/17)   Hepatic Venous Pressure Gradient Predicts Clinical Disease Progression in Patients With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis - (11/14/17)   Hepatic de Novo Lipogenesis Is Elevated in Patients With NASH Across the Spectrum of Disease Severity - (11/14/17)   Reductions in Hepatic Proton Density Fat Fraction Predict Histologic Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)   Reductions in Liver Stiffness by Magnetic Resonance Elastography Predict Fibrosis Improvement in a Multicenter Clinical Trial of Subjects With Nonalcoholic Steatohepatitis - (11/14/17)   Serum Pro-C3 Is Associated With Hepatic Steatosis and Fibrosis, and Responsive to Changes in Steatosis in Patients With NASH - (11/13/17)   Prospective Validation of the Enhanced Liver Fibrosis (ELF) Test for the Prediction of Disease Progression in Patients With Nonalcoholic Steatohepatitis and Advanced Fibrosis - (11/13/17)   Prospective Validation of Hepatic Collagen Content for the Prediction of Clinical Disease Progression in Patients With Advanced Fibrosis Due to NASH - (11/13/17)   Gilead Announces Phase 2 Results for GS-0976 in Nonalcoholic Steatohepatitis (NASH) - (11/13/17)   Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (11/13/17)   Combination of ASK1 and ACC Inhibitors Increases Efficacy in Rodent Models of NASH - (11/13/17)   Evaluation of the Safety, Pharmacokinetics, and Pharmacodynamic Effects on de Novo Lipogenesis of the Acetyl-CoA Carboxylase Inhibitor GS-0976 in Healthy Volunteers - (11/13/17)   A Liver-Targeted Acetyl-CoA Carboxylase Inhibitor Increases Fatty Acid Oxidation, Improves Mitochondrial Function, and Reduces Bile Acids and Oxidative Stress in a Murine Model of NASH - (11/13/17)   norUrsodeoxycholic acid (norUDCA) improves non-alcoholic fatty liver disease (NAFLD): Results from a randomized placebo-controlled, double-blind phase IIa study - (11/13/17)   Racial and Ethnic Disparities in Non-Alcoholic Fatty Liver Disease Prevalence, Severity, and Outcomes in the United States: A Meta-Analysis - (11/13/17)   Performance of liver stiffness by FibroScan in a Large Prospective Multicenter UK Study: Applicability, reliability, diagnostic performance and influence of the probe type and of steatosis on the liver stiffness measurement - (11/13/17)   The incidence of hepatocellular carcinoma is not increased after DAA therapy - (11/13/17)   Treatment of Hepatitis C Virus (HCV) Leads to Economic Gains Related to Reduction in Cases of Hepatocellular Carcinoma (HCC) and Decompensated Cirrhosis (DCC) in Japan - (11/13/17)   Impact of a Structured Hepatocellular Carcinoma Surveillance Program in Patients with Cirrhosis: Frequency, Evaluation and Subsequent Clinical Outcomes of Patients with Abnormal Imaging Findings - (11/13/17)   Improved Short-term Survival among HCV Patients following Liver Transplantation in the Era of Direct Acting Antiviral Agents - (11/13/17)   The Declining Burden of HCV on the Liver Transplant Waitlist associated with the DAA era - (11/13/17)   Treatment of HCV with Direct Acting Antivirals Significantly Reduces Liver-Related Hospitalizations in Patients with Cirrhosis - (11/13/17)   INCIDENCE OF HEPATITIS C AMONG HIV-INFECTED MEN WHO HAVE SEX WITH MEN IN SAN DIEGO, 2000-2015 - (11/10/17)   Risk of Hepatitis C transmission from antibody positive-nucleic acid negative liver organs to non-Hepatitis C recipients - (11/10/17)   Immunological assessment of HBeAg-negative Chronic Hepatitis B patient responses following anti-PD-1 treatment - (11/10/17)   Bi-weekly Dosing of ARB-1467 LNP siRNA in HBeAgNegative, Virally Suppressed Patients with Chronic HBV Infection Leads to Deeper Declines in HBsAg and Potential Association with IL28b - (11/10/17)   Pharmacokinetics and exploratory exposure-response of siRNAs administered monthly as ARB-001467 (ARB-1467) in a Phase 2a study in HBeAg positive and negative virally suppressed subjects with chronic hepatitis B - (11/10/17)   In Vivo Study of a LNP siRNA Investigational Agent Applied Sequentially with Immunomodulatory Treatments for Chronic Hepatitis B Infection - (11/10/17)   Antiviral Characterization of a Next Generation Chemical Series ofHBV Capsid Inhibitors In Vitro and In Vivo - (11/10/17)   Identification and Characterization of AB-452, a Potent Small Molecule HBV RNA Destabilizer In Vitro and In Vivo - (11/10/17)   Single Dose Safety, Tolerability and Pharmacokinetics of AB-423 in Healthy Volunteers from the ongoing Single and Multiple Ascending Dose Study AB-423-001 - (11/10/17)   Phase 1b Clinical trial of TG1050, a novel HBV-targeted immunotherapy, in NUC suppressed chronic hepatitis B patients: safety and early immunological data following single administration - (11/10/17)   Novel anti-viral activity of SB 9200, a RIGI agonist; results from Cohort 1 of the ACHIEVE trial - (11/08/17)   Bi-weekly Dosing of ARB-1467 LNP siRNA in HBeAgNegative, Virally Suppressed Patients with Chronic HBV Infection Leads to Deeper Declines in HBsAg and Potential Association with IL28b - (11/08/17)   Rapid Turnover of cccDNA in Chronic Hepatitis B Patients Who Have Failed Nucleoside Treatment Due to Emerging Resistance - (11/08/17)   Preclinical Profile of Potent Second Generation CpAMs Capable of Inhibiting the Generation of HBsAg, HBeAg, pgRNA and cccDNA in HBV Infected Cells - (11/08/17)   Functional Activation of NK and CD8+ T Cells In Vitro by the Toll-Like Receptor 8 Agonist GS-9688 - (11/08/17)   Cytokines Induced by GS-9688, a Toll-Like Receptor 8 Agonist, Inhibit HBV RNA, DNA, and Antigen Levels in Primary Human Hepatocytes - (11/08/17)   Evaluation of Factors Associated With Differences in ALT Normalization Between Virally Suppressed TAF- and TDF-Treated CHB Patients - (11/08/17)   Effect of TenofovirDisoproxyl(TDF) on Hepatocellular Carcinoma (HCC) Incidence in Patients with Chronic Hepatitis B (CHB) Compared to Untreated Patients:A Multicenter Study with Propensity Score Matching (PSM) - (11/08/17)   Safety and Efficacy of Vesatolimod (GS-9620) in Patients With Chronic Hepatitis B Who Are Not Currently on Antiviral Treatment - (11/08/17)   Improved Bone and Renal Safety at 1 Year After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide: Results From 2 Phase 3 Studies in HBeAg-Positive and HBeAg-Negative Patients With Chronic Hepatitis B - (11/08/17)   Phase 1a Safety and Pharmacokinetics (PK) of ABI-H0731, a Novel Core Protein Allosteric Modifier (CpAM) - (11/08/17)   Ledipasvir/Sofosbuvir in the Treatment of Japanese Patients With Chronic HCV Genotype 2 Infection - (11/08/17)   Identification of Novel HCV Genotype and Subtypes in Patients Treated with Sofosbuvir-Based Regimens - (11/08/17)   The road to elimination of Hepatitis C: Analysis of SVR versus new HCV infections in 91 countries - (11/08/17)   Regression of liver stiffness (LS) after direct acting anti-viral (DAA) therapy for hepatitis C in the country of Georgia - (11/06/17)   Real-World Effectiveness of Sofosbuvir and Ledipasvir/Sofosbuvir Based Regimens in Hepatitis C Virus Genotype 3 Infection Within National Hepatitis C Elimination Program in the Country of Georgia - (11/06/17)   Ledipasvir / Sofosbuvir plus Ribavirin as highly effective regimen for RF1_2k/1b patients within Georgian national hepatitis C elimination program - (11/06/17)   Efficacy and Safety of Tenofovir Alafenamide at 96 Weeks in Chronic HBV Patients With Risk Factors for Use of Tenofovir Disoproxil Fumarate - (11/01/17)   Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of JNJ-56136379, a Novel HBV Capsid Assembly Modulator, in Non-cirrhotic, Treatment-naïve Patients with Chronic Hepatitis B. - (11/01/17)   Safety and Efficacy of Glecaprevir/Pibrentasvir in Patients Aged 65 Years or Older With Chronic Hepatitis C: A Pooled Analysis of Phase 2 and 3 Clinical Trials - (10/28/17)   Pan-Genotypic Hepatitis C Treatment With Glecaprevir/Pibrentasvir Achieves Greatest Improvements in Quality-Adjusted Life-Years and Lifetime Risk Reductions in Liver-Related Morbidity and Mortality vs Standards of Care: A Cost-Utility Analysis - (10/28/17)   Hepatitis C in Patients Without Fibrosis or with Minimal Fibrosis: The Impact of Treatment and Sustained Virologic Response on Patient-Reported Outcomes - (10/28/17)   Significant and Sustained Improvement of Health-Related Quality of Life Scores in Patients with Hepatitis C and Sustained Virologic Response - (10/28/17)   Treatment with Glecaprevir/Pibrentasvir (G/P)-based regimens of patients with difficult to treat HCV infection. A compassionate use study. - (10/28/17)   Impact of Hepatitis C Treatment With Glecaprevir + Pibrentasvir on Patient's Health Related Quality of Life: Results From Phase 3 CERTAIN Trials - (10/28/17)   Chronic kidney disease and hepatitis C mutually advance liver and renal disease progression: real-world evidence from the United States - (10/27/17)   Pan-genotypic Hepatitis C Treatment With Glecaprevir+ Pibrentasvir Resulted in Improvement in Cardiovascular and Metabolic Extrahepatic Manifestations and Stable Renal Function: Results From Phase 3 Clinical Trials - (10/27/17)   New York City Hospitals' Capacity to Support the Elimination of Hepatitis C: A Follow-up Survey - (10/27/17)   Acetyl-CoA Carboxylase Inhibitor GS-0976 Leads to Significant Improvements in MRI-PDFF in a Phase 2, Randomized, Placebo-Controlled Trial of Patients with NASH - (10/27/17)   Nivolumab in Sorafenib-Naive and -Experienced Patients With Advanced Hepatocellular Carcinoma: Survival, Hepatic Safety, and Biomarker Assessments in CheckMate-040 - (10/26/17)   BMS-986036 (PEGylated FGF21) in Patients with Non-Alcoholic Steatohepatitis: A Phase 2 Study - (10/26/17)   Adherence to Pangenotypic Glecaprevir/Pibrentasvir Treatment and SVR12 in HCV-infected Patients: An Integrated Analysis of the Phase 2/3 Clinical Trial Program - (10/26/17)   Efficacy and Safety of Sofosbuvir/Velpatasvir Plus Ribavirin for 12 or 24 Weeks in Genotype 1 or 2 HCV-infected Japanese Patients with Prior Treatment Failure to DAA-Based Regimens - (10/26/17)   HEPATITIS C VIRUS REINFECTION AND INJECTING RISK BEHAVIOR FOLLOWING ELBASVIR/GRAZOPREVIR TREATMENT IN PARTICIPANTS ON OPIATE AGONIST THERAPY: C-EDGE CO-STAR PART B - (10/26/17)   Susceptibility to Voxilaprevir of NS3 Resistance-Associated Substitutions and Clinical Isolates From Direct-Acting Antiviral-Experienced and -Naïve Patients - (10/26/17)   No Resistance to Tenofovir Alafenamide Detected Through 96 Weeks of Treatment in Patients with Chronic Hepatitis B - (10/26/17)   A5327 Sofosbuvir-Containing Regimens Without Interferon for Treatment of Acute HCV in HIV-1-infected Individuals (SWIFT-C) - (10/24/17)   A Phrase 3, French Multicenter, Open-Label Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve HCV GT1b-Infected Patients with non-severe Fibrosis: STREAGER study - (10/24/17)   Impact of Sustained Virologic Response with Direct-Acting Antiviral Treatment on Mortality and Hepatocellular Carcinoma - significantly lower mortality, HCC 60% to 84% - (10/24/17)   Eradication of HCV induced by DAAs is associated with a 71% reduction in HCC risk - (10/24/17)   Randomized Controlled Trial of Cash Incentives or Peer Mentors to Improve HCV Linkage and Treatment Among HIV/HCV Coinfected Persons Who Inject Drugs: The CHAMPS Study - (10/24/17)   The Impact of Hepatitis C Diagnosis on Substance-Use Behaviors in Patients Engaged in Opioid Substitution Therapy - HCV screening/diagnosis reduces drug use by 33% (non-prescribed opioids, benzodiazepines and cocaine) - (10/24/17)   Efficacy, Safety, and Pharmacokinetics of Glecaprevir/Pibrentasvir in Adults With Chronic Genotype 1-6 Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis - (10/24/17)   Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread® - (10/24/17)   Exercise improves age-related inflammation, liver damage and cancer. - (10/23/17)   Safety and Efficacy of Ledipasvir/Sofosbuvir in a Genotype 1 HCV-Infected Chinese Population: Results From a Phase 3, Clinical Trial - (10/23/17)   Evaluation of the efficacy and tolerability of JNJ-4178 (AL-335, odalasvir, and simeprevir) in hepatitis C virus-infected patients without cirrhosis: The Phase IIb OMEGA-1 study - (10/23/17)   Efficacy and Safety of Glecaprevir/Pibrentasvir for 8 or 12 Weeks in Treatment-naïve Patients with Chronic HCV Genotype 3: An Integrated Phase 2/3 Analysis - (10/23/17)   Do resistance associated substitutions (RAS) or Ribavirin (RBV) use influence treatment success of Sofosbuvir (SOF)/Velpatasvir (VEL) in chronic hepatitis C genotype 3 (GT 3) infection? - Results from the GErman hepatitis C COhort (GECCO) - (10/23/17)   C-BREEZE-2: Efficacy and Safety of a Two-Drug Direct-Acting Antiviral Agent Regimen Ruzasvir 180 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, 5, or 6 - (10/23/17)   Safety and Efficacy of Elbasvir/Grazoprevir in Asian Participants With Hepatitis C Virus Genotypes 1 and 4 Infection: An Integrated Analysis of Data From 11 Phase 2/3 Trials - (10/23/17)   Safety and Efficacy of 12 Weeks of Elbasvir (EBR)/Grazoprevir (GZR) in Hepatitis C Virus (HCV) GT1- and GT4-Infected Participants 65 Years and Older: An Integrated Analysis of Twelve Clinical Trials - (10/23/17)   SOF/VEL/VOX for 12 Weeks in NS5A-Inhibitor-Experienced HCV-Infected Patients: Results of the Deferred Treatment Group in the Phase 3 POLARIS-1 Study - (10/23/17)   Safety and Efficacy of Treatment With Once-Daily Ledipasvir/Sofosbuvir (90/400 mg) for 12 Weeks in Genotype 1 HCV-Infected Patients With Severe Renal Impairment - (10/23/17)   Economic Burden of Chronic Hepatitis C (CHC) in Medicaid and Commercially Insured Patients in the United States - (10/23/17)   Epidemiologic Impact of Expanding Chronic Hepatitis C (CHC) Treatment in People Who Inject Drug in the United States: A Mathematical Model Using Data From the C-EDGE CO-STAR Study - (10/23/17)   Real-World Cost-Effectiveness of Elbasvir/Grazoprevir (EBR/GZR) in Treatment-Naïve (TN) Patients With Chronic Hepatitis C (CHC) Virus Genotype 1 (GT1) in the United States (US) - (10/23/17)   A Pragmatic Approach to Optimizing the Efficacy of Elbasvir/Grazoprevir Using Baseline Viral Load in Participants With Hepatitis C Virus Genotype 1a Infection: A Post Hoc Analysis of 11 Clinical Trials - (10/23/17)   Safety and efficacy of the combination Sofosbuvir-Ledipasvir in HCV mono-infected patients from the French observational Cohort ANRS CO22 HEPATHER The ANRS-AFEF HEPATHER study group - (10/23/17)   Impact of treatment duration and ribavirin (RBV) addition on real-world effectiveness of elbasvir/grazoprevir (EBR-GZR) in select patient subgroups with Genotype 1 (GT1) Chronic Hepatitis C (HCV): Retrospective Data Analyses from the Trio Network. - (10/23/17)   Perceived Barriers Related to the Management of HCVInfection Among Physicians Prescribing Opioid Agonist Therapy:The C-SCOPE Study - (10/23/17)   Gilead Announces Multiple Scientific Presentations Demonstrating High Cure Rates in Difficult-to-Cure HCV Patients and Improved Long-Term Bone and Renal Safety of Vemlidy® in HBV Patients Switched from Viread® - (10/23/17)   Merck to Present New Data on ZEPATIER® (elbasvir and grazoprevir) for the Treatment of Chronic Hepatitis C Virus Infection at The Liver Meeting® 2017 - (10/20/17)   AbbVie Demonstrates Leadership in HCV with New MAVYRET™ (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017 - (10/17/17)